-
Roberts, AW, Seymour, JF, Brown, JR, Wierda, WG, Kipps, TJ, Khaw, SL, Carney, DA, He, SZ, Huang, DCS, Xiong, H, et al.
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease.
Journal of Clinical Oncology
30(5)
:
488 -496
2012
view publication
-
Khaw, SL, Huang, DCS, Roberts, AW.
Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies.
Pathology
43(6)
:
525 -535
2011
view publication
-
High, LM, Szymanska, B, Wilczynska-Kalak, U, Barber, N, O'Brien, R, Khaw, SL, Vikstrom, IB, Roberts, AW, Lock, RB.
The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs.
Molecular Pharmacology
77(3)
:
483 -494
2010
view publication
-
Khaw, SL, Huang, DC, He, S, Seymour, JF, Carney, D, Mason, KD, Chyla, B, Litvinovich, E, McKeegan, E, Krivoshik, A, et al.
Biomarkers and In Vivo Responses to the BH3 Mimetic, ABT-263, in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)..
Blood
114(22)
:
2374
2009
view publication
-
Mason, KD, Khaw, SL, Rayeroux, KC, Chew, E, Lee, EF, Fairlie, WD, Grigg, AP, Seymour, JF, Szer, J, Huang, DCS, et al.
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
Leukemia
23(11)
:
2034 -2041
2009
view publication